Olejniczak Dominik, Dera Paulina, Religioni Urszula, Duda-Zalewska Aneta, Deptała Andrzej
Public Health Division, Medical University of Warsaw, Warsaw, Poland.
Collegium of Socio-Economics, Warsaw School of Economics, Warsaw, Poland.
Contemp Oncol (Pozn). 2016;20(1):80-5. doi: 10.5114/wo.2016.58504. Epub 2016 Mar 16.
To check the degree of acceptance of, inclination for, and barriers in genetic testing for gene mutations that increase the risk of breast and ovarian cancers among female residents of Warsaw.
This study involved 562 women between 20 and 77 years of age, all of whom were patients visiting gynaecologists practising in clinics in the City of Warsaw. The studied population was divided into six age categories. The study method was a diagnostic poll conducted with the use of an original questionnaire containing 10 multiple-choice questions.
Nearly 70% of the women showed an interest in taking a test to detect predispositions to develop breast and ovarian cancer. More than 10% did not want to take such a test, while every fifth women was undecided. No statistically significant differences between the respondents' willingness to pay and education were found (p = 0.05). The most frequent answer given by women in all groups was that the amount to pay was too high. Such an answer was given by 52.17% of women with primary education, 65.22% of women with vocational education, 58.61% of women with secondary education, and 41.62% of women with higher education.
Women with a confirmed increased risk of developing breast and/or ovarian cancer due to inter alia the presence of BRCA1 and BRCA2 gene mutations should pay particular attention to 1(st) and 2(nd) level prophylaxis.
调查华沙女性居民对增加乳腺癌和卵巢癌风险的基因突变检测的接受程度、倾向及障碍。
本研究纳入了562名年龄在20至77岁之间的女性,她们均为在华沙市诊所就诊的妇科患者。研究人群分为六个年龄组。研究方法是使用一份包含10个多项选择题的原始问卷进行诊断性调查。
近70%的女性表示有兴趣进行检测以发现患乳腺癌和卵巢癌的易感性。超过10%的女性不想进行此类检测,而每五名女性中就有一名犹豫不决。在受访者的支付意愿和教育程度之间未发现统计学上的显著差异(p = 0.05)。所有组中女性给出的最常见答案是费用太高。小学教育程度的女性中有52.17%给出了这样的答案,职业教育程度的女性中有65.22%,中等教育程度的女性中有58.61%,高等教育程度的女性中有41.62%。
由于存在BRCA1和BRCA2基因突变等原因而确诊患乳腺癌和/或卵巢癌风险增加的女性,应特别关注一级和二级预防措施。